Table 2.
Treatments and pathological reports.
| Parameters | n (%) |
|---|---|
| Surgical procedures | |
| Lobectomy | 114 (91.9) |
| Bilobectomy (RUL and RML) | 1 (0.8) |
| Bilobectomy (RLL and RML) | 9 (7.3) |
| Histologic types | |
| Adenocarcinoma | 70 (56.5) |
| Squamous cell carcinoma | 33 (26.6) |
| Bronchioloalveolar carcinoma | 10 (8.1) |
| Large cell carcinoma | 5 (4.0) |
| Neuroendocrine tumor | 3 (2.4) |
| Adenoid cystic CA | 2 (1.6) |
| Adenosquamous | 1 (0.8) |
| Tumor grading | |
| Well differentiated | 41 (33.1) |
| Moderately differentiated | 45 (36.3) |
| Poorly differentiated | 24 (19.4) |
| Undifferentiated | 5 (4.0) |
| Mucinous type (BAC) | 5 (4.0) |
| Nonmucinous type (BAC) | 4 (3.2) |
| Pathological staging | |
| IA | 33 (26.6) |
| IB | 45 (36.3) |
| IIA | 21 (16.9) |
| IIB | 25 (20.2) |
| Tumor diameter (cm) | 4.8 ± 2.7 |
| ≤3 | 33 (26.6) |
| >3 | 91 (73.4) |
| Tumor necrosis | 48 (38.7) |
| Visceral pleural invasion | 23 (18.6) |
| Neural invasion | 2 (1.6) |
| Intratumoral lymphatic invasion | 91 (73.4) |
| Intratumoral blood vessel invasion | 40 (32.3) |
| Follow-up time (months) | 29.1 ± 24.6 |
| Tumor recurrence | 53 (42.7) |
| Death | 47 (37.9) |